Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 23.13
NXTM's Cash to Debt is ranked higher than
71% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. NXTM: 23.13 )
Ranked among companies with meaningful Cash to Debt only.
NXTM' s 10-Year Cash to Debt Range
Min: 0.5  Med: 3.68 Max: No Debt
Current: 23.13
Equity to Asset 0.62
NXTM's Equity to Asset is ranked higher than
55% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NXTM: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
NXTM' s 10-Year Equity to Asset Range
Min: -4.58  Med: 0.60 Max: 0.89
Current: 0.62
-4.58
0.89
F-Score: 3
Z-Score: 5.08
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -6.81
NXTM's Operating margin (%) is ranked lower than
71% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. NXTM: -6.81 )
Ranked among companies with meaningful Operating margin (%) only.
NXTM' s 10-Year Operating margin (%) Range
Min: -37110  Med: -38.82 Max: -4.63
Current: -6.81
-37110
-4.63
Net-margin (%) -7.16
NXTM's Net-margin (%) is ranked lower than
70% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. NXTM: -7.16 )
Ranked among companies with meaningful Net-margin (%) only.
NXTM' s 10-Year Net-margin (%) Range
Min: -36600  Med: -39.77 Max: -6.26
Current: -7.16
-36600
-6.26
ROE (%) -11.95
NXTM's ROE (%) is ranked lower than
71% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. NXTM: -11.95 )
Ranked among companies with meaningful ROE (%) only.
NXTM' s 10-Year ROE (%) Range
Min: -491.86  Med: -33.44 Max: -8.69
Current: -11.95
-491.86
-8.69
ROA (%) -7.33
NXTM's ROA (%) is ranked lower than
70% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. NXTM: -7.33 )
Ranked among companies with meaningful ROA (%) only.
NXTM' s 10-Year ROA (%) Range
Min: -94.54  Med: -24.24 Max: -5.02
Current: -7.33
-94.54
-5.02
ROC (Joel Greenblatt) (%) -18.02
NXTM's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. NXTM: -18.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NXTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -637.26  Med: -77.48 Max: -20.17
Current: -18.02
-637.26
-20.17
Revenue Growth (3Y)(%) 6.80
NXTM's Revenue Growth (3Y)(%) is ranked higher than
60% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. NXTM: 6.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NXTM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 24.90 Max: 373.3
Current: 6.8
0
373.3
EBITDA Growth (3Y)(%) -11.50
NXTM's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. NXTM: -11.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NXTM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.2  Med: -32.55 Max: 1.5
Current: -11.5
-62.2
1.5
» NXTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

NXTM Guru Trades in Q3 2014

Jim Simons 67,600 sh (New)
RS Investment Management 2,206,428 sh (+28.48%)
Steven Cohen 1,005,300 sh (+3.30%)
» More
Q4 2014

NXTM Guru Trades in Q4 2014

Jim Simons 126,990 sh (+87.86%)
RS Investment Management 2,301,042 sh (+4.29%)
Steven Cohen 495,200 sh (-50.74%)
» More
Q1 2015

NXTM Guru Trades in Q1 2015

Steven Cohen 994,705 sh (+100.87%)
RS Investment Management 2,477,574 sh (+7.67%)
Jim Simons 57,190 sh (-54.96%)
» More
Q2 2015

NXTM Guru Trades in Q2 2015

Paul Tudor Jones 16,200 sh (New)
RS Investment Management 3,601,254 sh (+45.35%)
RS Investment Management 3,601,254 sh (+45.35%)
Steven Cohen 1,269,600 sh (+27.64%)
Steven Cohen 3,163,744 sh (+218.06%)
Steven Cohen 600,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 34.25
NXTM's Forward P/E is ranked lower than
81% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. NXTM: 34.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.60
NXTM's P/B is ranked lower than
79% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. NXTM: 5.60 )
Ranked among companies with meaningful P/B only.
NXTM' s 10-Year P/B Range
Min: 0.8  Med: 4.26 Max: 14.22
Current: 5.6
0.8
14.22
P/S 3.26
NXTM's P/S is ranked lower than
57% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. NXTM: 3.26 )
Ranked among companies with meaningful P/S only.
NXTM' s 10-Year P/S Range
Min: 0.66  Med: 3.61 Max: 16.71
Current: 3.26
0.66
16.71
Current Ratio 3.04
NXTM's Current Ratio is ranked higher than
66% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. NXTM: 3.04 )
Ranked among companies with meaningful Current Ratio only.
NXTM' s 10-Year Current Ratio Range
Min: 1.71  Med: 3.50 Max: 10.48
Current: 3.04
1.71
10.48
Quick Ratio 1.98
NXTM's Quick Ratio is ranked higher than
62% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. NXTM: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
NXTM' s 10-Year Quick Ratio Range
Min: 0.75  Med: 2.59 Max: 9.59
Current: 1.98
0.75
9.59
Days Inventory 84.52
NXTM's Days Inventory is ranked higher than
78% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. NXTM: 84.52 )
Ranked among companies with meaningful Days Inventory only.
NXTM' s 10-Year Days Inventory Range
Min: 80.86  Med: 99.35 Max: 611.57
Current: 84.52
80.86
611.57
Days Sales Outstanding 30.59
NXTM's Days Sales Outstanding is ranked higher than
91% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. NXTM: 30.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
NXTM' s 10-Year Days Sales Outstanding Range
Min: 26.56  Med: 34.32 Max: 190.16
Current: 30.59
26.56
190.16

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 102.81
NXTM's Price/Net Current Asset Value is ranked lower than
97% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.89 vs. NXTM: 102.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NXTM' s 10-Year Price/Net Current Asset Value Range
Min: 2.77  Med: 20.89 Max: 112.06
Current: 102.81
2.77
112.06
Price/Tangible Book 7.87
NXTM's Price/Tangible Book is ranked lower than
73% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. NXTM: 7.87 )
Ranked among companies with meaningful Price/Tangible Book only.
NXTM' s 10-Year Price/Tangible Book Range
Min: 2.39  Med: 6.38 Max: 106.11
Current: 7.87
2.39
106.11
Price/Projected FCF 149.55
NXTM's Price/Projected FCF is ranked lower than
98% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. NXTM: 149.55 )
Ranked among companies with meaningful Price/Projected FCF only.
NXTM' s 10-Year Price/Projected FCF Range
Min: 129.86  Med: 281.18 Max: 432.5
Current: 149.55
129.86
432.5
Price/Median PS Value 0.91
NXTM's Price/Median PS Value is ranked higher than
63% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. NXTM: 0.91 )
Ranked among companies with meaningful Price/Median PS Value only.
NXTM' s 10-Year Price/Median PS Value Range
Min: 0.24  Med: 0.96 Max: 3.88
Current: 0.91
0.24
3.88
Earnings Yield (Greenblatt) (%) -2.12
NXTM's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. NXTM: -2.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NXTM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -89.8  Med: 0.00 Max: 0
Current: -2.12
-89.8
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 328 370 413
EPS($) 0.17 0.48 0.67
EPS without NRI($) 0.17 0.48 0.67

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:N5X.Germany,
NxStage Medical Inc was incorporated in Delaware in 1998 under the name QB Medical, Inc., and later changed its name to NxStage Medical, Inc. NxStage is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its main product, the NxStage System One was designed to satisfy an unmet clinical need for a system that could deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that could be used by healthcare professionals and trained lay users alike in a number of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent, or 'daily,' dialysis. The System One is cleared by the United States Food and Drug Administration for home hemodialysis as well as hospital and clinic-based dialysis. It also sells needles and blood tubing sets mainly to dialysis clinics for the treatment of End Stage Renal Disease, or ESRD. The Company has two reporting segments, System One and In-Center. It distributes its products in three markets: the home, critical care and in-center. Within the System One segment, the Company sells and rentals System One and PureFlow SL equipment and sells disposable products in the home and critical care markets. The home market consists of dialysis centers that provide treatment options for patients that have ESRD, while the critical care market consists of hospitals or facilities that treat patients that have suddenly, and possibly temporarily, lost kidney function. The company sells essentially the same System One cyclers and disposables within each market and some of the company's largest customers in the home market provide outsourced renal dialysis services to hospitals in the critical care market to which the company sells System One cyclers and disposables. Sales of products to both markets are made through dedicated sales forces and products are distributed directly to the customer. Within the In-Center segment, the Company sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. Nearly all In-Center products are sold through national distributors. The Company competes with Fresenius, Gambro, Nipro, Baxter International, Inc., or Baxter, JMS and others. The Company is subject to government regulation in the countries in which it conducts business. In the foreign countries in which the Company market and sell its products, it is subject to local regulations affecting, among other things, design and product standards, packaging and labeling and promotion requirements.
» More Articles for NXTM

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 17 2010 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 12,000 Shares Dec 16 2010 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 16 2010 

More From Other Websites
American Journal of Kidney Disease Publication Confirms Significant Patient Advantages with HHD... Sep 01 2015
American Journal of Kidney Disease Publication Confirms Significant Patient Advantages with HHD... Sep 01 2015
NXSTAGE MEDICAL, INC. Financials Aug 14 2015
Nxstage (NXTM) Shares March Higher, Can It Continue? Aug 13 2015
NxStage System One Now in Eight of Top 10 U.S. Nephrology Hospitals Aug 12 2015
NxStage System One Now in Eight of Top 10 U.S. Nephrology Hospitals Aug 12 2015
10-Q for NxStage Medical, Inc. Aug 09 2015
Edited Transcript of NXTM earnings conference call or presentation 6-Aug-15 1:00pm GMT Aug 06 2015
NxStage Medical Inc Earnings Call scheduled for 9:00 am ET today Aug 06 2015
NxStage reports 2Q loss Aug 06 2015
NxStage reports 2Q loss Aug 06 2015
NxStage Reports Record Second Quarter Financial Results And Improves Financial Guidance For 2015 Aug 06 2015
NxStage Celebrates 10th Anniversary of the Revolutionary System One; Unveils Robust Pipeline and... Aug 06 2015
NXSTAGE MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2015
NxStage Celebrates 10th Anniversary of the Revolutionary System One; Unveils Robust Pipeline and... Aug 06 2015
NxStage Reports Record Second Quarter Financial Results And Improves Financial Guidance For 2015 Aug 06 2015
Q2 2015 NxStage Medical Inc Earnings Release - Before Market Open Aug 06 2015
Mesa Laboratories, Inc.: Leads amongst peers with strong fundamentals Aug 04 2015
NxStage Announces Third Quarter 2015 Investor Conference Schedule Jul 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK